TST003

News alerts, weekly reports and conference planners

Company:

Transcenta

Drug class:

Gremlin-1 inhibitor

‹

›

2ms

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov)

P1/2, N=111, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Jun 2026

2 months ago

Trial completion date • Trial primary completion date • First-in-human

TST003

over1year

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (clinicaltrials.gov)

P1/2, N=111, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | N=76 --> 111

over 1 year ago

Enrollment closed • Enrollment change • Metastases

TST003

almost3years

The preclinical characterization of TST003, a first-in-class mAb targeting gremlin-1 overexpressed by cancer-associated fibroblasts and tumor cells (AACR 2023)

In summary, TST003 is a first-in-class therapeutic mAb targeting Gremlin-1 overexpressed by CAFs and tumor cells. Our preclinical characterization results provided the rationale for on-going clinical evaluation of TST003 in patients with advanced solid tumors with high unmet medical need either as monotherapy or in combination with SoC.

almost 3 years ago

Preclinical • PD(L)-1 Biomarker • IO biomarker • Tumor cell

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TGFB1 (Transforming Growth Factor Beta 1)

KRAS G12D • PD-L1 negative • KRAS G12

TST003